Select Page

46% of NET patients are
diagnosed at an advanced stage

How Can I Help?

Latest News

AMEND Presents at SICEM 2024 in South Korea

AMEND Presents at SICEM 2024 in South Korea

AMEND CEO, Jo Grey, was honoured to be invited to give a presentation at the 2024 Seoul International Congress of Endocrinology & Metabolism (SICEM) meeting in April, organised by the Korean Endocrine Society.  The special symposium, Multiple endocrine neoplasia:...

read more